Salarius Pharmaceuticals Files Q1 2025 10-Q

Ticker: DCOY · Form: 10-Q · Filed: May 14, 2025 · CIK: 1615219

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

Related Tickers: SLRX

TL;DR

Salarius Pharma (SLRX) filed their Q1 2025 10-Q. Financials look steady.

AI Summary

Salarius Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Flex Pharma, Inc., is based in Houston, TX. Financial details such as common stock, additional paid-in capital, and retained earnings are reported for various periods including March 31, 2025, December 31, 2024, and March 31, 2024.

Why It Matters

This filing provides investors with the latest financial snapshot of Salarius Pharmaceuticals, Inc., detailing their financial health and performance for the first quarter of 2025.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Salarius Pharmaceuticals is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Salarius Pharmaceuticals, Inc.?

Salarius Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].

When was Salarius Pharmaceuticals, Inc. formerly known as?

Salarius Pharmaceuticals, Inc. was formerly known as Flex Pharma, Inc., with a date of name change on 20140730.

What is the fiscal year end for Salarius Pharmaceuticals, Inc.?

The fiscal year end for Salarius Pharmaceuticals, Inc. is December 31 (1231).

What is the business address of Salarius Pharmaceuticals, Inc.?

The business address is 2450 HOLCOMBE BLVD, SUITE J-608, HOUSTON, TX 77021.

What is the SEC file number for Salarius Pharmaceuticals, Inc.?

The SEC file number for Salarius Pharmaceuticals, Inc. is 001-36812.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Salarius Pharmaceuticals, Inc. (DCOY).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing